Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas

Chinese Medical Journal

Volumn 120, Issue 18, 2007, Pages 1597-1605

  Zhang, Yun Gang ^a   Du, Juan ^a   Tian, Xin Xia ^a   Zhong, Yan Feng ^a   Fang, Wei Gang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Beta catenin; Cathepsin D; Ductal breast carcinomas; E cadherin; Matrix metalloproteinase 2

Indexed keywords

BETA CATENIN; CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B; MOLECULAR MARKER; PROGESTERONE RECEPTOR; PROTEIN PS2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UVOMORULIN;

ACCURACY; ADULT; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PROTEIN EXPRESSION; STROMA CELL;

EID: 35348983565     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200709020-00010     Document Type: Article

References (44)

1. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005; 17: 499-508.
2. Fidler IJ, Radinsky R. Search for genes that suppress cancer metastasis. J Natl Cancer Ins 1996; 88: 1700-1703.
3. Chen HC, Chu RY, Hsu PN, Hsu PI, Lu JY, Lai KH, et al. Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas. Cancer Lett 2003; 201: 97-106.
4. Li Z, Ren Y, Lin SX, Liang YJ, Liang HZ. Association of E-cadherin and beta-catenin with metastasis in nasopharyngeal carcinoma. Chin Med J 2004; 117: 1232-1239.
5. Sun W, Herrera GA. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. Hum Pathol 2002; 33: 996-1000.
6. Koksal IT, Ozcan F, Kilicaslan I, Tefekli A. Expression of E-cadherin, in prostate, cancer in formalin-fixed, paraffin-embedded tissues: correlation with pathological features-Pathology 2002; 34: 233-238.
7. Kanazawa T, Watanabe T, Kazama S, Tada T, Koketsu S, Nagawa H. Poorly differentiated adenocarcinoma, and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer 2002; 102: 225-229.
8. Yoshida R, Kimura N, Harada. Y, Ohuchi N. The loss of E-cadherin, alpha- and beta-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer. Int J Oncol 2001; 18: 513-520.
9. Sarrio D, Perez-Mies B, Hardisson D, Moreno-Bueno G, Suarez A, Cano A, et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004; 23: 3272-3283.
10. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K. Expression of E-cadherin as related to other prognostic factors and survival in breast cancer. J Pathol 1994; 174: 101-109.
11. Gonzalez MA, Pinder SE, Wencyk PM, Bell JA, Elston CW, Nicholson RI, et al. An immunohistochemical examination of the expression of E-cadherin, alpha- and beta/gamma-catenins, and alpha2- and beta 1 -integrins -in invasive breast cancer. J Pathol 1999; 187: 523-529.
12. Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, et al. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 2001 193: 433-441.
13. Tan DS, Potts HW, Leong AC, Gillett CE, Skilton D, Harris WH, et al. The biological and prognostic significance of cell polarity and E-cadherin in grade 1 infiltrating ductal carcinoma of the breast. J Pathol 1999; 189: 20-27.
14. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-2252.
15. Sheen-Chen SL, Chen HS, Eng HL, Sheen CC, Cheng WJ. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett 2001; 173: 79-82.
16. Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, et al. Increased gelatinase-A and gelatinase-B activities in malignant vs benign breast tumors. Int J Cancer 2000; 86: 204-207.
17. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 is associated with survival in breast carcinoma. Br J Cancer 2003; 89: 1270-1275.
18. Djonov V, Cresto N, Aebersold DM. Tumor cell specific expression of MMP-2 correlates with tumor vascularisation in breast cancer. Int J Oncol 2002; 21: 25-30.
19. Kuvaja P, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma. Oncology 2005; 68: 196-203.
20. Ondruschka C, Buhtz P, Motsch C, Feigang B, Schneider-stock R, Roessner A, et al. Prognostic value of MMP-2, -9 and TRAP-1, -2 immunoreactive protein at the invasive front in advanced head and neck squamous cell carcinomas. Pathol Res Pract 2002; 98: 509-515.
21. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997; 3: 1623-1628.
22. Westley B, Rochefort H. Estradiol induced proteins in the MCF-7 human breast cancer cell line. Biochem Biophys Res Commun 1979; 90: 410-416.
23. Cavailles V, Garcia M, Rochefort H. Regulation of cathepsin D mRNA and pS2 gene expression by growth factors in MCF-7 human breast cancer cells. Mol Endocrinol 1989; 3: 552-558.
24. Tetu B, Brisson J, Lapointe H, Wang CS, Bernard P, Blanchette C. Cathepsin D expression by cancer and stromal cells in breast cancer: an immunohistochemical study of 1348 cases. Breast Cancer Res Treat 1999; 55: 137-147.
25. Zheng WQ, Looi LM, Cheah PL. Correlation between laminin and cathepsin D expressions in breast carcinoma. Tumori 2002; 88: 296-299.
26. Niu Y, Fu X, Lv A, Fan Y, Wang Y. Potential markers predicting distant metastasis in axillary node-negative breast carcinoma. Int J Cancer 2002; 98: 754-760.
27. Henry JA, McCarthy AL Angus B, Westley BR, May FE, Nicholson S, et al. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer: an immunohistochemical study. Cancer 1990; 65: 265-271.
28. Aziz S, Pervez S, Khan S, Kayani N, Rahbar M. Immunohistochemical cathepsin-D expression in breast cancer: correlation with established pathological parameters and survival. Pathol Res Pract 2001; 197: 551-557.
29. Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, et al. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Anticancer Res 2004; 24: 2061-2068.
30. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, et al. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol 1993; 11: 36-43.
31. Nakopoulou L, Tsirmpa I, Alexandrou P, Louvrou A, Ampela C, Markaki S, et al. MMP-2 protein in invasive breast cancer and the impact of MMP-2/ TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 2003; 77: 145-155.
32. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998; 185: 262-266.
33. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993; 53: 1696-1701.
34. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 2004; 202: 265-273.
35. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003; 5: 217-222.
36. Berx G, Van Roy F. The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 2001; 3: 289-293.
37. Cleton-Jansen AM. E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 2002; 4: 5-8.
38. Hatsell S, Rowlands TR, Hiremath M, Cowin P. The role of β-catenin and Tcfs in mammary development and neoplasia. J Mammary Gland Biol Neoplasia 2003; 8: 145-158.
39. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 2002; 40: 536-546.
40. Kanai Y, Ochiai A, Shibata T. c-erbB-2 gene product directly associates with beta-catenin and plakoglobin. Biochem Biophys Res Commun 1995; 208: 1067-1072.
41. Shibata T, Ochiai A, Kanai Y. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 1996; 13: 883-889.
42. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004; 88: 75-85.
43. Goldberg GI, Strongin A, Collier IE, Genrich IT, Marmer BL. Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 1992; 267: 4583-4591.
44. Duffy MJ, Blaser J, Duggan C, McDermott E, O'Higgins N, Fennelly JJ, et al. Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer. Br J Cancer 1995; 71: 1025-1028.